Cargando…
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351336/ https://www.ncbi.nlm.nih.gov/pubmed/30545968 http://dx.doi.org/10.1183/13993003.01913-2018 |
_version_ | 1783390555795881984 |
---|---|
author | Simonneau, Gérald Montani, David Celermajer, David S. Denton, Christopher P. Gatzoulis, Michael A. Krowka, Michael Williams, Paul G. Souza, Rogerio |
author_facet | Simonneau, Gérald Montani, David Celermajer, David S. Denton, Christopher P. Gatzoulis, Michael A. Krowka, Michael Williams, Paul G. Souza, Rogerio |
author_sort | Simonneau, Gérald |
collection | PubMed |
description | Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH. |
format | Online Article Text |
id | pubmed-6351336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-63513362019-02-06 Haemodynamic definitions and updated clinical classification of pulmonary hypertension Simonneau, Gérald Montani, David Celermajer, David S. Denton, Christopher P. Gatzoulis, Michael A. Krowka, Michael Williams, Paul G. Souza, Rogerio Eur Respir J Series Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH. European Respiratory Society 2019-01-24 /pmc/articles/PMC6351336/ /pubmed/30545968 http://dx.doi.org/10.1183/13993003.01913-2018 Text en Copyright ©ERS 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Series Simonneau, Gérald Montani, David Celermajer, David S. Denton, Christopher P. Gatzoulis, Michael A. Krowka, Michael Williams, Paul G. Souza, Rogerio Haemodynamic definitions and updated clinical classification of pulmonary hypertension |
title | Haemodynamic definitions and updated clinical classification of pulmonary hypertension |
title_full | Haemodynamic definitions and updated clinical classification of pulmonary hypertension |
title_fullStr | Haemodynamic definitions and updated clinical classification of pulmonary hypertension |
title_full_unstemmed | Haemodynamic definitions and updated clinical classification of pulmonary hypertension |
title_short | Haemodynamic definitions and updated clinical classification of pulmonary hypertension |
title_sort | haemodynamic definitions and updated clinical classification of pulmonary hypertension |
topic | Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351336/ https://www.ncbi.nlm.nih.gov/pubmed/30545968 http://dx.doi.org/10.1183/13993003.01913-2018 |
work_keys_str_mv | AT simonneaugerald haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension AT montanidavid haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension AT celermajerdavids haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension AT dentonchristopherp haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension AT gatzoulismichaela haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension AT krowkamichael haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension AT williamspaulg haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension AT souzarogerio haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonaryhypertension |